Travere Therapeutics: CEO Eric M Dube exercised 243,735 shares

What happened

• Eric M Dube, CEO, exercised options for 243,735 shares on Oct 15, 2026 (43,735 shares at $26.88 and 200,000 shares at $8.93) for a total exercise cost of $2,961,597, and sold 243,735 shares the same day in three open-market transactions for total proceeds of $13,116,670.
• The filing also reports corresponding derivative conversions shown as disposed at $0.00 (reflecting option-to-share conversion).

Key details

• Transaction date: Oct 15, 2026.
• Exercise details: 43,735 shares exercised at $26.88 ($1,175,597) and 200,000 shares exercised at $8.93 ($1,786,000); options described as fully vested and exercisable (footnotes F5, F6).
• Sales details: 128,065 shares sold at a weighted average price of $52.9672 (range $52.63–$53.6250) for $6,783,244 (F2); 37,270 shares sold at a weighted average price of $54.1997 (range $53.63–$54.62) for $2,020,023 (F3); 78,400 shares sold at a weighted average price of $55.0179 (range $54.63–$55.57) for $4,313,403 (F4).
• One of the sales was made pursuant to a written 10b5-1 trading plan adopted on Jun 16, 2026 (F1).
• Shares owned after the transaction: not disclosed in this filing.
• Filing date: Oct 19, 2026; filing was made within the Form 4 reporting window.

Why it may matter

• The filing shows exercised options and that the exercised shares were sold the same day, consistent with a cashless exercise and immediate disposition of the acquired shares.
• Footnotes indicate the option vesting schedule and that some sales were executed under a 10b5-1 plan; weighted average sale prices and price ranges are provided with notes that full per-price share counts are available on request.
• This filing does not show why the insider traded or why the company acted.